| Name | Title | Contact Details |
|---|
Optimum Outcomes is a Downers Grove, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Adare Pharma Solutions is a global contract development and manufacturing organization (CDMO) focused on oral dosage forms for the pharmaceutical industry. The company offers integrated services that span from product development to commercial manufacturing and packaging, with a strong emphasis on small molecule pharmaceuticals. With around 800 employees and seven facilities in the United States and Europe, Adare is well-equipped to serve markets worldwide. The company specializes in technologies such as taste masking, customized release, and solubility enhancement, addressing unique formulation challenges. Adares product development services include formulation development, analytical method validation, and support for various regulatory submissions. Their manufacturing capabilities encompass a range of processes, including granulation, coating, and high potency manufacturing. Additionally, Adare operates a dedicated packaging facility that provides high-speed packaging solutions. The company serves a diverse customer base, including branded, specialty, generic, and veterinary pharmaceutical segments, and is committed to maintaining high regulatory standards across all operations.
3-V Biosciences, Inc. is discovering and developing therapeutics that modulate key pathways in oncology and infectious diseases. In oncology, the company`s lead candidate is a first-in-class, oral fatty acid synthase (FASN) inhibitor in Phase 1 clinical development that has been shown to block tumor cell signaling pathways and induce tumor cell apoptosis. 3-V`s antiviral therapeutics have demonstrated the ability to block host-pathogen interactions, resulting in robust and broad-spectrum in vitro and in vivo antiviral activity, including efficacy against viruses resistant to other classes of antiviral drugs, and a high barrier to resistance. The 3-V team applies an integrated approach, leveraging internal expertise in biology, medicinal chemistry, drug discovery and development to drive programs forward. The company is located in Menlo Park, California.
MediciNova, Inc., a development stage biopharmaceutical company, focuses on acquiring and developing small molecule therapeutics for the treatment of serious diseases for the United States market. The company’s principal product candidates include MN-166, an ibudilast-based drug candidate, which is in Phase I and Phase II clinical trials for the treatment of drug dependence and pain; and MN-221, a ß2 -adrenergic receptor agonist that has completed Phase II clinical trials for the treatment of acute exacerbations of asthma. It also has other product candidates in the clinical development for the treatment of acute exacerbations of asthma, multiple sclerosis and other central nervous system disorders, bronchial asthma, interstitial cystitis, solid tumor cancers, generalized anxiety disorders/insomnia, preterm labor, urinary incontinence, and thrombotic disorders. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.
ONE Bio Corp. is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.